Home>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Hydroxyzine pamoate

Hydroxyzine pamoate Sale

(Synonyms: 双羟萘酸羟嗪;拉姆酸羟嗪;扑姆酸羟嗪;双羟萘酸羟嗪) 目录号 : GC36279

Hydroxyzine Pamoate is the pamoate salt form of hydroxyzine, a synthetic piperazine histamine H1-receptor antagonist with anti-allergic, antispasmodic, sedative, anti-emetic and anti-anxiety properties.

Hydroxyzine pamoate Chemical Structure

Cas No.:10246-75-0

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥594.00
现货
25mg
¥540.00
现货
50mg
¥900.00
现货
100mg
¥1,485.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Hydroxyzine Pamoate is the pamoate salt form of hydroxyzine, a synthetic piperazine histamine H1-receptor antagonist with anti-allergic, antispasmodic, sedative, anti-emetic and anti-anxiety properties.

Chemical Properties

Cas No. 10246-75-0 SDF
别名 双羟萘酸羟嗪;拉姆酸羟嗪;扑姆酸羟嗪;双羟萘酸羟嗪
Canonical SMILES O=C(C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1)O.ClC5=CC=C(C(N6CCN(CCOCCO)CC6)C7=CC=CC=C7)C=C5
分子式 C44H43ClN2O8 分子量 763.27
溶解度 DMSO: 250 mg/mL (327.54 mM) 储存条件 Store at -20°C,sealed storage, away from moisture
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.3102 mL 6.5508 mL 13.1015 mL
5 mM 0.262 mL 1.3102 mL 2.6203 mL
10 mM 0.131 mL 0.6551 mL 1.3102 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Conscious sedation of pediatric dental patients: an investigation of chloral hydrate, Hydroxyzine pamoate, and meperidine vs. chloral hydrate and Hydroxyzine pamoate

Pediatr Dent 1991 Jan-Feb;13(1):10-9.PMID:1945978doi

This study evaluated two oral sedative regimens for the conscious sedation of pediatric dental patients (mean age 37.0 months) unmanageable by traditional behavior management techniques. Regimen A included chloral hydrate (Noctec--E.R. Squibb and Sons, Princeton, NJ) at 50 mg/kg with 25 mg Hydroxyzine pamoate (Vistaril--Pfizer Laboratories, New York, NY), plus meperidine (Demerol--Winthrop-Breon, New York, NY) at 1.5 mg/kg. Regimen B included chloral hydrate at 50 mg/kg with 25 mg Hydroxyzine pamoate. In a crossover research design, 10 patients were assigned randomly to receive one regimen, to be followed by the alternative regimen during the second appointment. The primary purpose of this study was to determine if meperidine would improve patient behavior, and increase the prevalence of respiratory compromise. A secondary purpose of the study was to develop an objective method to assess behavior during the conscious sedation of pediatric dental patients. Results revealed that the addition of oral meperidine to chloral hydrate and Hydroxyzine pamoate resulted in improved behavior (P less than 0.01) during local anesthetic injection, rubber dam delivery, and the operative dental procedure. There was no increase in the prevalence of respiratory compromise with the addition of meperidine.